Protein Therapeutics Market 2020-2024- Featuring AbbVie Inc., Amgen Inc., AstraZeneca Plc, Among Others to Contribute to the Market Growth | Industry Analysis, Market Trends, Opportunities, and Forecast 2024 | Technavio
The protein therapeutics market is poised to grow by USD 82.47 bn during 2020-2024, progressing at a CAGR of over 7% during the forecast period.
Worried about the impact of COVID-19 on your Business? Here is an Exclusive report talking about Market scenarios, Estimates, the impact of lockdown, and Customer Behaviour.
The report on the protein therapeutics market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
The report offers an up-to-date analysis regarding the current global market scenario and the overall market environment. The market is driven by increased demand for mAbs.
The protein therapeutics market analysis includes product segment and geography landscape. This study identifies the development of novel therapies using innovative technologies as one of the prime reasons driving the protein therapeutics market growth during the next few years.
This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
The protein therapeutics market covers the following areas:
Point of Care Diagnostics Market by Product, End-user, and Geography - Forecast and Analysis 2020-2024- The point of care diagnostics market size has the potential to grow by USD 10.69 billion during 2020-2024. However, the market's growth momentum will decelerate during the forecast period. To get extensive research insights: Click and get a FREE sample report in minutes
Prostate Biopsy Market by Product, End-user, and Geography - Forecast and Analysis 2020-2024- The prostate biopsy market size has the potential to grow by USD 380.23 million during 2020-2024, and the market's growth momentum will accelerate during the forecast period. To get extensive research insights: Click and get a FREE sample report in minutes
Key Topics Covered:
Executive Summary
Market Landscape
Market ecosystem
Market characteristics
Value chain analysis
Market Sizing
Market definition
Market segment analysis
Market size 2019
Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
Five Forces Summary
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
Market Segmentation by Product
Market segments
Comparison by Product
mAbs - Market size and forecast 2019-2024
Human insulin - Market size and forecast 2019-2024
Erythropoeitin - Market size and forecast 2019-2024
Clotting factors - Market size and forecast 2019-2024
Others - Market size and forecast 2019-2024
Market opportunity by Product
Market segmentation by Therapy Area
Market segments
Metabolic and endocrine disorders
Hematopoiesis
Fertility
Cancer
Autoimmune diseases
Infectious diseases
Protein vaccine
Market segmentation by Protein Function
Market segments
Enzymatic and regulatory activity
Special targeting activity
Vaccines
Protein diagnostics
Customer Landscape
Geographic Landscape
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2019-2024
Europe - Market size and forecast 2019-2024
APAC - Market size and forecast 2019-2024
South America - Market size and forecast 2019-2024
MEA - Market size and forecast 2019-2024
Key leading countries
Market opportunity by geography
Market drivers
Market challenges
Market trends
Vendor Landscape
Overview
Landscape disruption
Vendor Analysis
Vendors covered
Market positioning of vendors
AbbVie Inc.
Amgen Inc.
AstraZeneca Plc
Eli Lilly and Co.
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
Merck & Co. Inc.
Novo Nordisk AS
Pfizer Inc.
Sanofi
Appendix
Scope of the report
Currency conversion rates for US$
Research methodology
List of abbreviations
Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavio's in-depth research has direct and indirect COVID-19 impacted market research reports.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
According to a new report published by Dialogue Health Technologies Inc., Canada's leading health and wellness virtual care platform, Canadians' overall well-being is at a low point as they struggle with lifestyle challenges around sleep and physical...
Applied Biological Laboratories Inc, the biotechnology company behind the innovative new cold and flu remedy Biovanta and other scientifically validated natural products, has named Rob Keen its new CEO, effective April 24.
"I am...
Zoomd Technologies Ltd. and its wholly-owned subsidiary Zoomd Ltd. (collectively, "Zoomd" or the "Company"), the marketing technology (MarTech) user-acquisition and engagement platform, today reported its financial results for the three months and...
Catheter Precision, Inc. ($VTAK), a leading MedTech company specializing in innovative products for cardiac electrophysiology, including its VIVO™ and LockeT products, announces that is has received its first purchase order (PO) for LockeT...
Moderna, Inc. and OpenAI today announced their ongoing collaboration to co-innovate with a shared vision of AI's transformative potential in the future of...
Arrowhead Pharmaceuticals, Inc. announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB, the company's investigational RNA interference (RNAi) therapeutic, in up to 66 healthy volunteers and...